Routine Cryptococcal Antigen Screening in Solid Organ
Background. Cryptococcosis affects 1 in 270 solid organ transplant (SOT) recipients with high mortality. In HIV-infected patients, cryptococcal antigen (CRAG) is detectable in blood weeks to months before symptomatic infection and screening is recommended. No screening guidelines exist for SOT recipients.
Methods. We performed a cost-effectiveness analysis of CRAG screening amongst SOT recipients. We estimated costs of screening from Medicare reimbursement of $16.49 for CPT 87899 (Infectious agent antigen detection by immunoassay). We determined the number at risk from a large cohort of 42,634 adult SOT recipients from ICD-9 CM billing data from HCUP State Inpatient Databases of Florida (2006 -2012 ), New York (2006 -2011 ), and California (2004 -2010 . Cost of screening was compared with the cost of inpatient hospitalization.
Results. Among 42,634 adult SOT recipients, 158 (0.37%) developed cryptococcosis at a median time of 15.5 months (range 0.1 -80) after transplant. During the 43 month follow-up, there was approximately 2.5% annual mortality. The estimated cost of hospital care for cryptococcal meningitis per person is approximately $70,000 in 2016 with current explosive cost of flucytosine at ~$29,000 per 2 weeks. Thus, the total estimated cost of hospital care in the cohort would be $11.0 million in 2016. In comparison, the cost to screen all 42,634 SOT recipients every three months would be $8.8 million. If CRAG screening could detect 75% of asymptomatic cryptococcal antigenemia prior to symptomatic disease requiring prolonged hospitalization, it would be approximately cost neutral ($11.5 million), and even cost saving if above 80% of hospitalizations are averted. Alternatively stated, for every one hospitalization avoided, 4245 persons could be CRAG screened for similar cost and likely better outcome.
Conclusion. Assuming the ability of routine screening to identify 75% of patients who would develop invasive cryptococcosis; CRAG screening every 3 months among SOT recipients likely would be at least cost neutral to the healthcare system. Antecedent duration of cryptococcal antigenemia prior to symptomatic disease in Non-HIV/SOT cohorts to inform optimal screening intervals should be further studied. Prospective SOT cohorts should validate this approach to save lives in a cost-effective manner.
Disclosures. Methods. We have conducted four pre-clinical studies in rhesus macaques to assess the safety, antiviral efficacy and dosing strategies of galidesivir against ZIKV infection. Collectively, we have challenged 70 rhesus macaques by various routes using 1x10 5 TCID 50 of a Puerto Rican ZIKV isolate. We have evaluated galidesivir therapy administered via IM injection as early as 90 minutes and up to 72 hours after subcutaneous (SC) ZIKV challenge, and as late as 5 days after intravaginal (IVAG) challenge. In these studies, we evaluated the efficacy of a range of loading and maintence doses of galidesivir. The highest dose evaluated has been a loading dose of 100mg/kg BID followed by a maintenance dose of 25mg/kg BID for nine days. We followed multiple endpoints, including ZIKV RNA levels in plasma, urine, saliva, and cerebrospinal fluid. Immune activation, complete blood counts, chemistries and galidesivir pharmacokinetics were also monitored.
Results. Galidesivir was well-tolerated in all studies. All untreated controls developed high-level plasma viremia, and had readily detectable ZIKV RNA in CSF, saliva and urine post-infection. Animals treated in the first 24 hours after SC ZIKV challenge did not develop plasma viremia and were either negative or had significantly reduced ZIKV RNA in bodily fluids. Animals treated with galidesivir later (up to 72 hours) were partially protected; they had detectable plasma ZIKV RNA, but the onset was delayed and/or magnitude significantly reduced compared with controls. Animals infected IVAG were protected by galidesivir treatment up until day 5 after infection, with no blood viremia and significant reductions in ZIKV RNA in the CSF as compared with controls.
Conclusion. Galidesivir dosing in rhesus macaques was well-tolerated and offered significant protection against ZIKV infection. These results warrant continued study and clinical evaluation. United States, are now in the unique position of providing care to both pregnant women with locally-transmitted and travel-associated ZIKV infections. This study provides data regarding the testing and pregnancy outcomes of women with laboratory evidence of ZIKV infection in pregnancy.
Methods. A retrospective chart review was conducted using laboratory records of ZIKV testing (PCR and IgM) completed from January through December 2016 at multiple tertiary care centers located in Miami-Dade County. Testing was based on CDC guidelines at time of testing, leading to heterogeneity in tests performed. Data was extracted from charts of women with positive ZIKV PCR in serum and/or urine or positive ZIKV IgM with confirmatory, pending, or insufficient PRNT results. Routine obstetrics parameters and the presence of fetal or neonatal abnormalities were recorded.
Results. Of the 2327 pregnant women screened for ZIKV, 88 (3.8%) screened positive with PCR and/or IgM in serum or urine. Of those women with positive ZIKV testing, 53 (60%) had no documented ZIKV symptoms and 40 (45%) had no known travel history outside of Miami-Dade County during their pregnancy. Sixtysix women had antenatal ultrasounds, 14 (21%) of which ever had a head circumference or biparetial diameter measurement less than the third percentile, but none showed evidence of intracranial calcifications. Fifty-four women with positive testing have delivered: 46 at term and 8 preterm. Fifty-four infants have been born to women with positive ZIKV testing; 2 infants (1.98%) had documented congenital abnormalities. One infant was born with clinically-defined microcephaly (1.9%) and intracranial calcifications and the other had only intracranial calcifications. Ninetyfour positive IgM tests were sent to the CDC for confirmatory plaque reduction neutralization testing (PRNT). 49 PRNT tests returned positive (ZIKV titer ≥10), while 28 returned negative (ZIKV titer < 10), representing a false-positive rate of 30.4%.
Conclusion. As this epidemic persists, data from this unique cohort of pregnant women with both local and travel-associated ZIKV exposure contributes to the growing knowledge base regarding implications of ZIKV in pregnancy.
Disclosures. All authors: No reported disclosures. Background. The objective of the present study was to identify drivers of the ZIV epidemic in the state of Rio de Janeiro to predict where the next hotspots will occur and prioritize areas for vector control and eventual vaccination once available.
Environmental and Climatic Risk Factors for Zika and Chikungunya Virus
Methods. To assess climatic and socio-economic drivers of arbovirus epidemics, we mapped rainfall, temperature, and sanitation infrastructure in the municipalities where individuals with laboratory confirmed cases of arboviral infection resided using our spatial pattern risk model.
Results. From March 2015 to May 2016, 3,916 participants from 58 municipalities in the state of Rio de Janeiro were tested for dengue, Chikungunya (CHKV), and ZIKV by RT-PCR and enzyme immunoassays. During the same period, 69,256 suspected cases of dengue, CHKV, and ZIKV were reported to the Rio Health Department, including 23,983 of dengue, 44,572 of ZIKV, and 701 of CHKV. Laboratory confirmed cases included 29 cases (0.7%) of dengue, 1,717 of ZIKV (43.8%), and 2,170 of CHKV (55.4%). Rains in Rio began in October 2015 and were followed one month later by the largest wave of the ZIKV epidemic (Figure 1 ). ZIKV cases markedly declined in February 2016, which coincided with the start of a CHKV outbreak. Rainfall predicted ZIKV and CHKV in Rio with a lead-time of 3 weeks each time. Social and environmental variables predicted the number of cases. The temporal dynamics of ZIKV and CHKV in Rio de Janeiro are explained by the shorter incubation period of the viruses in the mosquito vector; 2 days for CHKV vs 10 days for ZIKV.
Conclusion. The association between rainfall and ZIKV reflects vector ecology, as the larval stages of Aedes aegypti require pools of water to develop. Rainfall in October 2015 would have produced such pools resulting in increased mosquito abundance likely contributing to the ZIKV epidemic in humans the following month. The decrease in ZIKV in February 2016 and the increase in CHKV likely arose due to within-vector competition. The Pan American Health Organization's ZIKV Strategic Plan states that controlling arboviruses requires mapping their social and environmental drivers. Our findings contribute to such control efforts. 
